New Haven drug developer Achillion Pharmaceuticals Inc. promoted research chief Milind S. Deshpande to president of research and development, and named finance chief Mary Kay Fenton a senior vice president.
Previously executive vice president, Deshpande oversees Achillion’s development pipeline of small-molecule drugs aimed at thwarting infectious diseases, such as hepatitis C. He remains chief scientific officer.
Fenton, who was a vice president, remains chief financial officer.
